CD274 and cancer: In 2018, a study of IMpower133 demonstrated significantly longer progression-free survival (PFS) and overall survival (OS) in patients with small cell lung cancer (SCLC), which is traditionally considered a “recalcitrant cancer” (4), with atezolizumab (commercialized anti-PD-L1) being used based on traditional chemotherapy (etoposide combined with carboplatin) (5).